Photo of Oliver Hodgkiss

Oliver Hodgkiss

Oliver Hodgkiss is an associate in the firm’s global life sciences transactions team. He advises multinational and emerging companies in the life sciences sector on transactions at all stages of the product life-cycle. Oliver’s practice focuses on strategic collaborations, licensing, supply and manufacturing arrangements, and other commercial and IP matters relating to drug development and commercialisation. Oliver also regularly advises clients on commercial and IP due diligence in connection with their strategic M&A transactions.

Following the UK’s departure from the EU, the UK Government has been exploring ways to leverage its new regulatory freedoms. In particular, the life sciences sector has been a key Government priority. As early as January 2021, for example, the Government granted the MHRA powers to fast-track approvals for innovative medicines. More recently, two reports from Westminster bodies have proposed a new regulatory regime for so-called “nutraceuticals” (products that are part drug, part nutritional) to encourage investment.Continue Reading Growing calls for separate Nutraceutical regulation in the UK